Cargando…

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation

We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established Vero cell plat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganneru, Brunda, Jogdand, Harsh, Daram, Vijaya Kumar, Das, Dipankar, Molugu, Narasimha Reddy, Prasad, Sai D., Kannappa, Srinivas V., Ella, Krishna M., Ravikrishnan, Rajaram, Awasthi, Amit, Jose, Jomy, Rao, Panduranga, Kumar, Deepak, Ella, Raches, Abraham, Priya, Yadav, Pragya D., Sapkal, Gajanan N., Shete-Aich, Anita, Desphande, Gururaj, Mohandas, Sreelekshmy, Basu, Atanu, Gupta, Nivedita, Vadrevu, Krishna Mohan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944858/ https://www.ncbi.nlm.nih.gov/pubmed/33723528 http://dx.doi.org/10.1016/j.isci.2021.102298

Ejemplares similares

Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model
por: Yadav, Pragya D., et al.
Publicado: (2022)

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021)

Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants
por: Vadrevu, Krishna Mohan, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study
por: Vadrevu, Krishna Mohan, et al.
Publicado: (2022)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021)

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
por: Sunagar, Raju, et al.
Publicado: (2022)

Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern
por: Mohandas, Sreelekshmy, et al.
Publicado: (2022)

SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021)

Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters
por: Mohandas, Sreelekshmy, et al.
Publicado: (2022)

Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants
por: Patil, Dilip R., et al.
Publicado: (2023)

Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine
por: Vadrevu, Krishna Mohan, et al.
Publicado: (2019)

A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India
por: Reddy, Raghu, et al.
Publicado: (2021)

A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India
por: Ella, Raches, et al.
Publicado: (2018)

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
por: Yadav, Pragya D., et al.
Publicado: (2021)

Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection
por: Mohandas, Sreelekshmy, et al.
Publicado: (2020)

Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin(®))
por: Singh, Chandramani, et al.
Publicado: (2023)

Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model
por: Yadav, Pragya, et al.
Publicado: (2022)

Possible Role of Accessory Proteins in the Viral Replication for the 20I/501Y.V1 (B.1.1.7) SARS CoV-2 Variant
por: Nyayanit, Dimpal A., et al.
Publicado: (2021)

Authors’ response
por: Mukhopadhyay, Labanya, et al.
Publicado: (2021)

Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates
por: Mukhopadhyay, Labanya, et al.
Publicado: (2021)

Genomic characterization, transcriptome analysis, and pathogenicity of the Nipah virus (Indian isolate)
por: Mohandas, Sreelekshmy, et al.
Publicado: (2023)

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
por: Ella, Raches, et al.
Publicado: (2021)

A qualitative IgG ELISA for detection of SARS-CoV-2-specific antibodies in Syrian hamster serum samples
por: Shete, Anita, et al.
Publicado: (2021)

Reduced severity of SARS-CoV-2 infection by Kappa variant of interest (B.1.617.1) in a healthcare worker post-vaccination from Gujarat, India
por: Sahay, Rima Rakeshkumar, et al.
Publicado: (2022)

Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant
por: Shete, Anita M., et al.
Publicado: (2022)

Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG
por: Sapkal, Gajanan, et al.
Publicado: (2020)

SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera
por: Sahay, Rima R., et al.
Publicado: (2022)

Discovery of Hybrid Thiouracil–Coumarin Conjugates as Potential Novel Anti-SARS-CoV-2 Agents Targeting the Virus’s Polymerase “RdRp” as a Confirmed Interacting Biomolecule
por: Vishwanath, Divakar, et al.
Publicado: (2023)

Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran & China, & Italian tourists in India
por: Potdar, Varsha, et al.
Publicado: (2020)

A case with SARS-CoV-2 reinfection from India
por: Munivenkatappa, Ashok, et al.
Publicado: (2022)

Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis
por: Mourya, Devendra T., et al.
Publicado: (2020)

Identification and phylogenetic analysis of herpes simplex virus-1 from clinical isolates in India
por: Nyayanit, Dimpal A., et al.
Publicado: (2019)

Transcriptome & viral growth analysis of SARS-CoV-2-infected Vero CCL-81 cells
por: Nyayanit, Dimpal A., et al.
Publicado: (2020)

Development of Nipah virus-specific IgM & IgG ELISA for screening human serum samples
por: Shete, Anita M., et al.
Publicado: (2022)

Understanding the dynamics of IgM & IgG antibodies in COVID-19-positive patients
por: Kaduskar, Ojas, et al.
Publicado: (2022)

Broadly Reactive SARS-CoV-2-Specific T-Cell Response and Participation of Memory B and T Cells in Patients with Omicron COVID-19 Infection
por: Yadav, Pragya D., et al.
Publicado: (2023)

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster vaccination
por: Vadrevu, Krishna Mohan
Publicado: (2023)

Molecular characterization & recombination analysis of complete enterovirus-88 isolated from acute flaccid paralysis cases in India
por: Munivenkatappa, Ashok, et al.
Publicado: (2023)

Urinary immunoglobulins in viral diagnosis: An overview
por: Mohandas, Sreelekshmy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_frtilt4oltlkupf02dkpjhs7o2